The WuXiUPTM platform is an intensified perfusion culture process developed as a next-generation biomanufacturing solution that provides high-yield, high-quality drug products while being highly flexible and cost-effective. This platform adopts continuous harvest to greatly reduce the product residence time, which leads to high product quality.
As an integrated, intensified, continuous biologics manufacturing technology platform, WuXiUPTM drives improved economics, flexibility and quality, and is ideal for both labile or difficult-to-express proteins, as well as mAbs, bispecific Abs, Fc-fusion proteins and other recombinant proteins. WuXiUPTM has been applied to multiple projects at WuXi Biologics, providing comprehensive evaluation of this platform technology.
Other Features of WuXiUPTM Platform Include:
- Couples continuous upstream process with continuous direct product capture using multicolumn chromatography system operating in a periodic countercurrent (PCC) mode
- Dedicated DeltaV control system (Finesse) for celculture process and AKTA PCC chromatography systems and BioSMB system for purification
- Can be developed rapidly or converted from traditional fed-batch process without delaying CMC timelines